Australia's Oncosil Medical at two-week high on robust quarterly results
28/04/2026 04:29
** Shares of Oncosil Medical OSL.AX rise as much as 6.2% to A$0.515, their highest level since April 13 ** The medical device company says third-quarter revenue up 49% on pcp, with OncoSil Medical achieving strong growth across both dose volumes, revenue and commercially active treatment centres ** Third-quarter dose sales up 60% compared with pcp ** Oncosil stock down 46.6%, YTD (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com;))
Recent news on Oncosil Medical
See all newsAustralia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone
Brief: Oncosil Medical Says FDA Grants Hde Approval For Oncosil Device For Distal Cholangiocarcinoma
Brief: Oncosil Medical Posts FY26 Unit Sales Up 53%, Revenue Up 44% Versus FY25
Brief: Oncosil Medical Receives Saudi FDA Approval
Brief: Oncosil Medical Files For FDA Approval